Hemostasis Today

February, 2026
February 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
232425262728  
Sandra Revill Tremulis: The Major Trial Testing Whether Lp(a) Lowering Saves Lives
Feb 8, 2026, 14:27

Sandra Revill Tremulis: The Major Trial Testing Whether Lp(a) Lowering Saves Lives

Sandra Revill Tremulis, Marketing Consultant at Tremulis Stractical  Marketing Consulting and Founder of the Lipoprotein(a) Foundation, shared a post on LinkedIn about a recent article by Leslie Cho et al, published in American Heart Journal:

Pelacarsen — the major trial testing whether Lp(a) lowering saves lives

Pelacarsen outcomes program — Lp(a)HORIZON trial design/rationale

Executive summary: Defines the pivotal outcomes framework for Lp(a): large, multinational, placebo-controlled phase 3 trial in established CVD with elevated Lp(a), testing whether targeted Lp(a) lowering reduces MACE. Value for clinicians/researchers: clarifies inclusion thresholds, endpoints, event-driven design, and the intended inferential strategy—useful when interpreting forthcoming results and planning complementary studies (imaging, biomarkers, implementation).

This is one of the most important trials in cardiovascular medicine today.”

Title: Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a)

Authors: Leslie Cho , Stephen J Nicholls , Børge G Nordestgaard , Ulf Landmesser , Sotirios Tsimikas , Michael J Blaha , Eran Leitersdorf , A Michael Lincoff , Anastasia Lesogor , Brian Manning , Plamen Kozlovski , Hui Cao , Jing Wang , Steven E Nissen

Read the Full Article in American Heart Journal

Sandra Revill Tremulis: The Major Trial Testing Whether Lp(a) Lowering Saves Lives

Stay updated on all scientific advances with Hemostasis Today.